期刊文献+

CYP3A4和CYP3A5基因多态性与骨髓移植患者服用环孢素A所致肝损伤的相关性 被引量:3

Correlation between CYP3A4 and CYP3A5 polymorphisms and the susceptibility of hepatic injury induced by cyclosporine A in bone marrow transplant recipients
原文传递
导出
摘要 目的:检测骨髓移植患者CYP3A4*18B和CYP3A5*3基因型分布特征,探讨CYP3A4和CYP3A5基因多态性与骨髓移植患者服用环孢素A(cyclosporine A,CsA)所致肝损伤的相关性。方法:骨髓移植患者112例,肝功正常73例,肝功异常39例;测定CsA给药1周后的稳态血药浓度,应用聚合酶链反应(PCR)后直接测序的方法检测CYP3A4*18B和CYP3A5*3基因型分布及等位基因频率。结果:与肝功正常患者比较,肝功异常患者CYP3A4*18B和CYP3A5*3基因型及等位基因分布频率均无显著性差异(P>0.05);与CYP3A5*1/*1和CYP3A5*1/*3基因型比较,携带CYP3A5*3/*3基因型患者使用CsA1周后的标准化血药浓度(concentration-dose ratios,CDR)显著升高(P<0.05)。结论:携带CYP3A5*3/*3的患者CsA的CDR升高,CYP3A5*3基因多态性可能与骨髓移植患者服用CsA所致肝损伤相关。 OBJECTIVE To study the frequency distribution patterns of CYP3A4 * 18B and CYP3A5 * 3 polymorphisms in bone marrow transplant recipients, to explore the correlation between CYP3A4 and CYP3A5 polymorphisms and the suscepti- bility of hepatic injury induced by CsA in bone marrow transplant recipients. METHODS 112 cases of bone marrow transplant recipients were totally collected, 73 cases with normal hepatic function and 39 cases with abnormal hepatic function. The steady state concentration of CsA (C0) was measured after 1 week of administration using FPIA method. Polymerase chain reaction- direct sequencing methods were used to detect the genotype of CYP3A4 * 18B and CYP3A5* 3. RESUILTS There were no sig- nificant differences in the distribution of genotype of CYP3A4 * 18B and CYP3A5 * 3 between the groups of normal hepatic function and abnormal hepatic function (P)0.05); Compared with the genotypes CYP3A5 * 1/* 1 and CYP3A5 * 1/* 3 CDR of CsA was increased significantly in recipients with CYP3A5 * 3/* 3 (P〈0. 05). CONCLUSION CYP3A5* 3 polymorphisms may be correlated with much higher CDR of CsA. Therefore, we speculate that CYP3A5 * 3 may be a meaningful predictor of hepatic injury induced by CsA in bone marrow transplant recipients.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第21期1791-1795,共5页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金项目(编号:81102517)
关键词 骨髓移植患者 环孢素A 肝损伤 CYP3A4 CYP3A5 bone marrow transplant recipients cyclosporine A hepatic injury CYP3A4 * 18B CYP3A5 * 3
  • 相关文献

参考文献3

二级参考文献33

  • 1Hesselink DA, van-Schaik RH, van-der-Heiden IP, van-der-Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3AS, and MDR-I genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.Clin Pharmacol Ther 2003; 74: 245-54.
  • 2Anglicheau D, Thervet E, Etienne I, Hurault DLB, Le MY,Touchard G, et al. CYP3A5 and MDRI genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.Clin pharmacol Ther 2004; 75: 422-33.
  • 3Hesselink DA, van-Gelder T, van-Schaik RH, Balk AH, van-der-Heiden IP, van Dam T, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphism in the MDR-1,CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76:545-56.
  • 4Haufroid V, Mourad M, Van KV, Wawrzyniak J, De Meyer M,Eddour DC, et al. The effect of CYP3A5 and MDRI (ABCBI)polymorphism on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54.
  • 5Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66.
  • 6Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and emit cyclosporine assays. Clin Chem 1999; 45: 432-35.
  • 7Williams JA, Cook J, Susan I, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31: 1526-30.
  • 8Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555-64.
  • 9Aros CA, Ardiles LG, Schneider HO, Flores CA, Alruiz PA, Jerez VR, et al. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Transplant Proc 2005; 37: 3364-6.
  • 10Christians U, Sewing KF. Alternative cyclosporine metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-59.

共引文献365

同被引文献25

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部